Algernon management dumped the FAIMS device at Algernon which was the exact same technology Algernon (formerly Breathtec Biomedical) had been working on in 50/50 partnership with Cannabix Technologies Inc. The FAIMS device at Algernon was no more than a POC device for laboratories, scientist, whomever to chase whatever moloecules they desirerd. The FAIMS device was not targeting any specific disease. It was to be used as a tool for Research Use Only clientele. So, Algernon having dumped the FAIMS agreement and having ZERO to show for it's 3 year collaboration with Cannabix got royally screwed by Moreau. So what ever happened to the FAIMS device as intended by Aglernon? It is in the hands of Cannabix to commercialize it whenever that happens. From Cannabix website:
The Cannabix FAIMS device is designed to operate both independently or coupled in tandem directly to a mass spectrometer (MS), used in forensic labs. MS is considered the gold standard in toxicology for the analysis of drugs, poisons, and metabolites, due to its superior specificity and sensitivity. The highly selective Cannabix FAIMS device can potentially be employed in many related applications, either at the point of care or in the laboratory. The Cannabix FAIMS device is used in combination with the Breath Collection Unit. The Cannabix FAIMS device is at the advanced prototype stage.
Cannabix Technologies Inc. | FAIMS THC Breathalyzer System
The above description says nothing about chasing after drugs only. The tech was handed over to Kulwant Malhi and Algernon kicked rocks by going head first into the Repurposed Drugs Strategy. Moreau has driven the bus over the cliff every year since 2018. The stock sits at all time lows on a 1 for 100 reverse split basis. By all measures Moreau has been a colossal failure for shareholders. His only saving grace is getting the company off the OTC and onto NASDAQ ASAP. As I said, Malhi corrupts everyone and everything he touches. I'm sure Moreau is making his mum proud of all his hard work and million dollar annual pay.
Where’s the fool who cried us a river about Malhi being laid up in a wheelchair and having nothing to do with flipping bazillions of AGN shares to profit millions of dollars for another one of his dumpster fire companies? Who was flipping those shares while Malhi was supposedly down and out? Was it the former Chief Financial Officer of Algernon - Michael Sadhra? Sadhra, the guy who is a board of director at Malhi’s companies and bookkeeper as well. Sadhra, the guy who is a cubicle landlord for thousands of dollars per month in rent for the myriad of Bullrun companies including Algernon? That guy could not have left Algernon soon enough. Sadhra alone would be a Nasdaq uplist conflict of interest kill switch.
Bottom line is Moreau needs to grow the F up and take full responsibility for his blatant F ups year after year. Finally start doing right by shareholders. Get the Friggin uplist done already. Dump the IPF BS and find a friggin partner with cash and resources because management needs help with designing and executing real clinical trials and not those BS half baked studies that only spin the wheels of further dilution. We are 3+ years down the road with this Algernon stuff and not one true clinical trial has come out of the pipeline. It’s been an elaborate game of charades. Grow up Christopher. You’re not getting any younger right along with the rest of us. Don’t leave behind a legacy of greed. You can’t take it all with you and all money ain’t good money. What you hand down to heirs will either be a gift or a curse.